Defining the unknowns for cell therapies in Parkinson's disease

Defining the unknowns for cell therapies in Parkinson's disease

Bibliographic Details
Main Authors:	Emma L. Lane, Mariah J. Lelos
Format:	Article
Language:	English
Published:	The Company of Biologists 2022-10-01
Series:	Disease Models & Mechanisms
Subjects:	parkinson's disease cell therapy transplantation non-motor graft-induced dyskinesia neuroinflammation
Online Access:	http://dmm.biologists.org/content/15/10/dmm049543

Similar Items

Can cell and gene therapies improve cognitive symptoms in Parkinson’s disease?
by: Mariah J. Lelos
Published: (2022-04-01)

Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease
by: Eunju Shin, et al.
Published: (2012-09-01)

Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease
by: Emma Louise Lane, et al.
Published: (2009-07-01)

Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes
by: Lior eGreenbaum, et al.
Published: (2015-02-01)

Rhabdomyolysis Related to Dyskinesia in Parkinson’s Disease
by: Hesna Bektaş, et al.
Published: (2014-04-01)

Predictors of levo-dopa induced dyskinesias in Parkinson's disease
by: R T Athulya, et al.
Published: (2020-01-01)

Adipokines, Vitamin D, and Selected Inflammatory Biomarkers among Parkinson’s Disease Patients with and without Dyskinesia: A Preliminary Examination
by: Jan Milanowski, et al.
Published: (2024-02-01)

Identification and quantitative assessment of motor complications in Parkinson’s disease using the Parkinson’s KinetiGraph™
by: Yan Qu, et al.
Published: (2023-08-01)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
by: Valeria Conti, et al.
Published: (2022-05-01)

Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia
by: Joanna García, et al.
Published: (2011-09-01)

Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions
by: Lazzaro di Biase, et al.
Published: (2023-06-01)

Mucuna pruriens as adjunct therapy to levodopa in advanced Parkinson’s disease
by: Fernando Botello-Villagrana, et al.
Published: (2021-01-01)

Co-Application of C16 and Ang-1 Improves the Effects of Levodopa in Parkinson Disease Treatment
by: Fu XX, et al.
Published: (2022-07-01)

Comparison of the clinical response of stereotactic ventrointermedial thalamotomy with anatomical and pathophysiological features of parkinson's disease
by: VI. Tsymbaliuk, et al.
Published: (2017-12-01)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
by: Werner Poewe, et al.
Published: (2010-08-01)

Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease
by: Jinyoung Youn, et al.
Published: (2022-05-01)

Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease
by: Juan-Juan Du, et al.
Published: (2017-01-01)

Could New Generations of Sensors Reshape the Management of Parkinson’s Disease?
by: Oleg S. Levin, et al.
Published: (2021-09-01)

Amantadine in parkinson’s disease: modern possibilities of long-term therapy
by: V. V. Poleshchuk, et al.
Published: (2018-05-01)

Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease
by: A. A. Tappakhov, et al.
Published: (2020-02-01)

Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living
by: Etienne Goubault, et al.
Published: (2019-03-01)

Assessment of the Outcome of Stereotactic Unilateral Pallidotomy Surgery for Parkinson’s Disease
by: Mohamed Kabeil, et al.
Published: (2022-12-01)

Clinical features of drug-induced Parkinsonism
by: Nobuko Shiraiwa, et al.
Published: (2018-12-01)

Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease
by: Denis А. Abaimov, et al.
Published: (2021-06-01)

Genomic Analysis Identifies New Loci Associated With Motor Complications in Parkinson's Disease
by: Ho-Sung Ryu, et al.
Published: (2020-07-01)

Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
by: Ritam Bandopadhyay, et al.
Published: (2022-04-01)

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
by: Destany K. Kwon, et al.
Published: (2022-11-01)

Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia
by: Osama F. Elabi, et al.
Published: (2023-07-01)

Clinical profile of Parkinson's disease in the Gumei community of Minhang district, Shanghai
by: Kangyong Liu, et al.
Published: (2014-07-01)

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
by: Qian-Ya Fan, et al.
Published: (2022-09-01)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
by: Sharma VD, et al.
Published: (2018-04-01)

Drug therapy in patients with Parkinson’s disease
by: Müller Thomas
Published: (2012-05-01)

Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
by: Chang-Qing Zheng, et al.
Published: (2021-06-01)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
by: Bette S, et al.
Published: (2018-09-01)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
by: Stocchi F, et al.
Published: (2016-02-01)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
by: Aryun Kim, et al.
Published: (2018-05-01)

Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease
by: Felipe Patricio, et al.
Published: (2020-12-01)

Sequestration of Inflammation in Parkinson’s Disease via Stem Cell Therapy
by: Jonah Gordon, et al.
Published: (2022-09-01)

Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson’s disease
by: Sandy eStayte, et al.
Published: (2014-08-01)

Advances in non-dopaminergic pharmacological treatments of Parkinson's disease
by: Sandy eStayte, et al.
Published: (2014-05-01)